StromaCare Names Georges Rawadi as CEO

StromaCare, a French biotechnology company pioneering the discovery and development of cancer immunotherapies through stroma modulation, has appointed Georges Rawadi as chief executive officer (CEO).
 
Rawadi’s objectives include raising funds and building partnerships to support StromaCare’s lead product development towards clinical trials and continuing to develop the pipeline.
 
“I am very enthusiastic about Georges joining StromaCare as CEO,” said Philippe Archinard, president of the strategic committee at StromaCare. “His profound expertise in the biotechnology sector will facilitate StromaCare’s transition from a preclinical to a clinical stage company and will shape the company to meet the challenges related to its growth. I, along with the board, wish him every success in his new role.”
 
Rawadi brings over 20 years of experience in the pharma and biotech industry, having served in various key roles. Notable among his achievements are his positions as CEO and board member at Celyad Oncology (Belgium) and Ysopia Bioscience (France). Additionally, Rawadi has held significant roles as chief of biotech studio development at EureKare (France), vice-president BD & IP at Celyad Oncology and vice-president business development at Cellectis (France).
 
Rawadi holds a Ph.D. in microbiology and an executive master’s in management and strategy in the health industry. He is known for his passion in seeking and creating new business opportunities.
 
“I am very excited by the strong potential in StromaCare’s scientific and innovative approach, which will enable us to target a broad spectrum of solid cancers and overcome current treatment limitations. I am pleased to lead such a talented team and look forward to collaborating with individuals who share the same vision,” said Rawadi.